PMID- 22999748
OWN - NLM
STAT- MEDLINE
DCOM- 20130408
LR  - 20131121
IS  - 1535-7732 (Electronic)
IS  - 1051-0443 (Linking)
VI  - 23
IP  - 10
DP  - 2012 Oct
TI  - Safety and feasibility of same-day discharge of patients with unresectable 
      hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter 
      chemoembolization.
PG  - 1286-93.e1
LID - S1051-0443(12)00698-7 [pii]
LID - 10.1016/j.jvir.2012.07.003 [doi]
AB  - PURPOSE: The aim of this study was to investigate the safety and feasibility of 
      same-day discharge of patients with unresectable hepatocellular carcinoma (HCC) 
      after doxorubicin drug-eluting bead (DEB) transarterial chemoembolization and to 
      elucidate the factors predisposing to overnight admission. MATERIALS AND METHODS: 
      Consecutive patients with unresectable HCC who underwent superselective 100-300 
      mum DEB transarterial chemoembolization were included. The parameters of same-day 
      therapy (group A) were compared with those of patients admitted overnight (group 
      B). A chi2 test and a t test were used to compare categorical and continuous 
      variables accordingly. RESULTS: Seventy-six patients (mean, 61 y) received 110 
      DEB transarterial chemoembolization treatments over an 8-month study period. In 
      84.5% (93/110) of DEB transarterial chemoembolization procedures, the patients 
      were discharged on the same day (group A). The causes of hospitalization included 
      the worsening of comorbidities in 41.1% (7/17), pain control in 29.4% (5/17), and 
      groin and closure device-related complications in 29.4% (5/17) of patients. The 
      mean Charlson comorbidity scores in groups A and B were 6.96 (standard deviation 
      [SD] +/- 1.98) and 8.47 (SD +/- 2.18) (P = .0005), respectively. All of the patients 
      in group B had Barcelona Clinic Liver Cancer (BCLC) stages C and D HCC (P = 
      .024). There were no Common Terminology Criteria for Adverse Events (CTCAE) grade 
      III or worse adverse events (AEs). There was no mortality or emergency visits 
      within 30 days of discharge. CONCLUSIONS: Same-day discharge after superselective 
      DEB transarterial chemoembolization for unresectable HCC is safe and feasible. 
      BCLC C or D stage of disease, a higher Charlson comorbidity score, and groin or 
      closure device complications are correlated with a greater likelihood for 
      overnight admission.
CI  - Copyright (c) 2012 SIR. Published by Elsevier Inc. All rights reserved.
FAU - Prajapati, Hasmukh J
AU  - Prajapati HJ
AD  - Division of Interventional Radiology and Image Guided Medicine, Department of 
      Radiology, Winship Cancer Institute, Emory University School of Medicine, 
      Atlanta, Georgia 30322, USA.
FAU - Rafi, Shoaib
AU  - Rafi S
FAU - El-Rayes, Bassel F
AU  - El-Rayes BF
FAU - Kauh, John S
AU  - Kauh JS
FAU - Kooby, David A
AU  - Kooby DA
FAU - Kim, Hyun S
AU  - Kim HS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Vasc Interv Radiol
JT  - Journal of vascular and interventional radiology : JVIR
JID - 9203369
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Drug Carriers)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Aged
MH  - *Ambulatory Care
MH  - Antibiotics, Antineoplastic/*administration & dosage/adverse effects
MH  - Carcinoma, Hepatocellular/pathology/*therapy
MH  - *Chemoembolization, Therapeutic/adverse effects
MH  - Chi-Square Distribution
MH  - Comorbidity
MH  - Doxorubicin/*administration & dosage/adverse effects
MH  - *Drug Carriers
MH  - Feasibility Studies
MH  - Female
MH  - Georgia
MH  - Humans
MH  - Length of Stay
MH  - Liver Neoplasms/pathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - *Patient Discharge
MH  - Prospective Studies
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2012/09/25 06:00
MHDA- 2013/04/09 06:00
CRDT- 2012/09/25 06:00
PHST- 2011/12/22 00:00 [received]
PHST- 2012/06/28 00:00 [revised]
PHST- 2012/07/02 00:00 [accepted]
PHST- 2012/09/25 06:00 [entrez]
PHST- 2012/09/25 06:00 [pubmed]
PHST- 2013/04/09 06:00 [medline]
AID - S1051-0443(12)00698-7 [pii]
AID - 10.1016/j.jvir.2012.07.003 [doi]
PST - ppublish
SO  - J Vasc Interv Radiol. 2012 Oct;23(10):1286-93.e1. doi: 
      10.1016/j.jvir.2012.07.003.